Conditionally Active Costimulatory T Cell-Engager Programs for Autoimmunity & Solid-Tumor Indications
- Shifting from oncology’s maximum potency mindset to a safety-first model by optimizing immune thresholds for chronic B-cell or T-cell depletion
- Leveraging lessons from oncology to eliminate high-grade CRS and ICANS, ensuring a benign safety profile suitable for non-malignant, chronic indications
- Utilizing tissue-restricted targeting and refined dosing to achieve long-term immune reset while preserving overall patient safety